Bone mineral density and vitamin D in PCOS and hirsutism

References

• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81(1), 19–25 (2004).
   Web of Science ®Google Scholar
• Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol. Endocrinol 26(4), 281–296 (2010).
   PubMed Web of Science ®Google Scholar
• Azziz R, Sanchez LA, Knochenhauer ES et al. Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab. 89(2), 453–462 (2004).
   PubMed Web of Science ®Google Scholar
• Glintborg D, Hojlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 31(2), 328–334 (2008).
   PubMed Web of Science ®Google Scholar
• Glintborg D, Henriksen JE, Andersen M et al. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil. Steril. 82(6), 1570–1579 (2004).
   PubMed Web of Science ®Google Scholar
• Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J. Clin. Endocrinol. Metab. 91(3), 781–785 (2006).
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91(2), 456–488 (2009).
   PubMed Web of Science ®Google Scholar
• Wild RA, Carmina E, Diamanti-Kandarakis E et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab 95(5), 2038–2049 (2010).
   PubMed Web of Science ®Google Scholar
• Johnston CC Jr, Slemenda CW. Determinants of peak bone mass. Osteoporos. Int. 3( Suppl. 1), 54–55 (1993).
   PubMed Web of Science ®Google Scholar
• Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5 alpha-reductase activity in polycystic ovary syndrome. Lancet 335(8687), 431–433 (1990).
   PubMed Web of Science ®Google Scholar
• Lanzone A, Villa P, Fulghesu AM, Pavone V, Caruso A, Mancuso S. The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia. Hum. Reprod. 10(7), 1653–1657 (1995).
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Karras S, Goulis DG. Vitamin D in human reproduction: a narrative review. Int. J. Clin. Pract. 67(3), 225–235 (2013).
   PubMed Web of Science ®Google Scholar
• Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin. Endocrinol. (Oxf) 77(3), 343–350 (2012).
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack S, al Ali N, Qurttom M. Augmentation of bone mineral density in hirsute women. J. Clin. Endocrinol. Metab 82(9), 2821–2825 (1997).
   PubMed Web of Science ®Google Scholar
• Yuksel O, Dokmetas HS, Topcu S, Erselcan T, Sencan M. Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. J. Bone Miner. Metab. 19(4), 257–262 (2001).
   PubMed Web of Science ®Google Scholar
• Dixon JE, Rodin A, Murby B, Chapman MG, Fogelman I. Bone mass in hirsute women with androgen excess. Clin. Endocrinol. (Oxf) 30(3), 271–277 (1989).
   PubMed Web of Science ®Google Scholar
• Good C, Tulchinsky M, Mauger D, Demers LM, Legro RS. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil. Steril. 72(1), 21–25 (1999).
   PubMed Web of Science ®Google Scholar
• Gregoriou O, Kouskouni E, Bakas P et al. Bone mineral density in women with idiopathic hirsutism. Gynecol. Endocrinol. 14(5), 364–368 (2000).
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84(1), 165–169 (1999).
   PubMed Web of Science ®Google Scholar
• Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum. Reprod. 16(6), 1255–1260 (2001).
   PubMed Web of Science ®Google Scholar
• Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P. Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin. Endocrinol. (Oxf) 48(2), 169–173 (1998).
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M, Hagen C, Hermann AP. Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism. Clin. Endocrinol. (Oxf) 62(6), 683–691 (2005).
   PubMed Web of Science ®Google Scholar
• Prezelj J, Kocijancic A. Bone mineral density in hyperandrogenic amenorrhoea. Calcif. Tissue Int. 52(6), 422–424 (1993).
   PubMed Web of Science ®Google Scholar
• Noyan V, Yucel A, Sagsoz N. The association of bone mineral density with insulin resistance in patients with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 115(2), 200–205 (2004).
   PubMed Web of Science ®Google Scholar
• Schmidt J, Dahlgren E, Brannstrom M, Landin-Wilhelmsen K. Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome - a long-term follow-up study. Clin. Endocrinol. (Oxf) 77(2), 207–214 (2012).
   PubMed Web of Science ®Google Scholar
• Kassanos D, Trakakis E, Baltas CS et al. Augmentation of cortical bone mineral density in women with polycystic ovary syndrome: a peripheral quantitative computed tomography (pQCT) study. Hum. Reprod. 25(8), 2107–2114 (2010).
   PubMed Web of Science ®Google Scholar
• Rapuri PB, Kinyamu HK, Gallagher JC, Haynatzka V. Seasonal changes in calciotropic hormones, bone markers, and bone mineral density in elderly women. J. Clin. Endocrinol. Metab. 87(5), 2024–2032 (2002).
   PubMed Web of Science ®Google Scholar
• Compston JE. Sex steroids and bone. Physiol. Rev. 81(1), 419–447 (2001).
   PubMed Web of Science ®Google Scholar
• Notelovitz M. Androgen effects on bone and muscle. Fertil. Steril. 77( Suppl. 4), S34–S41 (2002).
   PubMed Web of Science ®Google Scholar
• Abu EO, Horner A, Kusec V, Triffitt JT, Compston JE. The localization of androgen receptors in human bone. J. Clin. Endocrinol. Metab. 82(10), 3493–3497 (1997).
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Pons F, Martinez de Osaba MJ, Garrido J, Fortuny A. Menstrual history as a determinant of current bone density in young hirsute women. Metabolism 45(4), 515–518 (1996).
   PubMed Web of Science ®Google Scholar
• Gregoriou O, Kouskouni E, Bakas P et al. Bone mineral density in women with idiopathic hirsutism. Gynecol. Endocrinol. 14(5), 364–368 (2000).
   PubMed Web of Science ®Google Scholar
• Boots LR, Potter S, Potter D, Azziz R. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertil. Steril. 69(2), 286–292 (1998).
   PubMed Web of Science ®Google Scholar
• Khosla S, Bilezikian JP. The role of estrogens in men and androgens in women. Endocrinol. Metab. Clin. North Am.. 32(1), 195–218 (2003).
   PubMed Web of Science ®Google Scholar
• Sasano H, Uzuki M, Sawai T et al. Aromatase in human bone tissue. J. Bone Miner. Res. 12(9), 1416–1423 (1997).
   PubMed Web of Science ®Google Scholar
• Khosla S, Melton LJIII, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 83(7), 2266–2274 (1998).
   PubMed Web of Science ®Google Scholar
• Douchi T, Yamamoto S, Oki T et al. Difference in the effect of adiposity on bone density between pre- and postmenopausal women. Maturitas 34(3), 261–266 (2000).
   PubMed Web of Science ®Google Scholar
• Orozco P, Nolla JM. Associations between body morphology and bone mineral density in premenopausal women. Eur. J. Epidemiol. 13(8), 919–924 (1997).
   PubMed Web of Science ®Google Scholar
• Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women. Metabolism 33(1), 68–75 (1984).
   PubMed Web of Science ®Google Scholar
• Christensen JO, Svendsen OL. Bone mineral in pre- and postmenopausal women with insulin-dependent and non-insulin-dependent diabetes mellitus. Osteoporos. Int. 10(4), 307–311 (1999).
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Rohold A, Henriksen JE, Beck-Nielsen H. Correlations between insulin sensitivity and bone mineral density in non-diabetic men. Diabet. Med. 17(2), 124–129 (2000).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Kritz-Silverstein D. Does hyperinsulinemia preserve bone? Diabetes Care 19(12), 1388–1392 (1996).
   PubMed Web of Science ®Google Scholar
• Krakauer JC, McKenna MJ, Rao DS, Whitehouse FW. Bone mineral density in diabetes. Diabetes Care 20(8), 1339–1340 (1997).
   PubMed Web of Science ®Google Scholar
• Frederiksen L, Hojlund K, Hougaard DM, Brixen K, Andersen M. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr.) 34(1), 145–156 (2012).
   PubMedGoogle Scholar
• Kenny AM, Kleppinger A, Annis K et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J. Am. Geriatr. Soc. 58(6), 1134–1143 (2010).
   PubMed Web of Science ®Google Scholar
• Douchi T, Oki T, Yamasaki H, Kuwahata R, Nakae M, Nagata Y. Relationship of androgens to muscle size and bone mineral density in women with polycystic ovary syndrome. Obstet. Gynecol. 98(3), 445–449 (2001).
   PubMed Web of Science ®Google Scholar
• Yanazume Y, Kawamura Y, Kuwahata A et al. Difference in non-weight-bearing effects on bone mineral density between trunk and peripheral fat mass in women with polycystic ovary syndrome. J. Obstet. Gynaecol. Res. 36(2), 352–356 (2010).
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2), 165–176 (1998).
   PubMed Web of Science ®Google Scholar
• Geusens P. Emerging treatments for postmenopausal osteoporosis-focus on denosumab. Clin. Interv. Aging 4, 241–250 (2009).
   PubMed Web of Science ®Google Scholar
• Nybo M, Rasmussen LM. Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells. Atherosclerosis 201(1), 33–35 (2008).
   PubMed Web of Science ®Google Scholar
• D'Amelio P, Isaia G, Isaia GC. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J. Endocrinol. Invest. 32(4 Suppl.), 6–9 (2009).
   PubMedGoogle Scholar
• Davenport C, Ashley DT, O'sullivan EP et al. Identifying coronary artery disease in men with type 2 diabetes: osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk. J. Hypertens. 29(12), 2469–2475 (2011).
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Botella-Carretero JI, Martinez-Garcia MA, Luque-Ramirez M, Alvarez-Blasco F, San Millan JL. Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. Eur. J. Endocrinol. 159(3), 225–232 (2008).
   PubMed Web of Science ®Google Scholar
• Pepene CE, Ilie IR, Marian I, Duncea I. Circulating osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Eur. J. Endocrinol. 164(1), 61–68 (2011).
   PubMed Web of Science ®Google Scholar
• Glintborg D, Hermann AP, Rasmussen LM, Andersen M. Plasma osteoprotegerin is associated with testosterone levels but unaffected by pioglitazone treatment in patients with polycystic ovary syndrome. J. Endocrinol. Invest. 36(7), 460–465 (2012).
   PubMed Web of Science ®Google Scholar
• Turner A, Chen TC, Barber TW, Malabanan AO, Holick MF, Tangpricha V. Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects. Clin. Endocrinol. (Oxf) 61(5), 560–566 (2004).
   PubMed Web of Science ®Google Scholar
• Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 60(10), 1475–1481 (2011).
   PubMed Web of Science ®Google Scholar
• Thomson RL, Spedding S, Brinkworth GD, Noakes M, Buckley JD. Seasonal effects on vitamin D status influence outcomes of lifestyle intervention in overweight and obese women with polycystic ovary syndrome. Fertil. Steril. 99(6), 1779–1785 (2013).
   PubMed Web of Science ®Google Scholar
• Panidis D, Balaris C, Farmakiotis D et al. Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin. Chem. 51(9), 1691–1697 (2005).
   PubMed Web of Science ®Google Scholar
• Mahmoudi T, Gourabi H, Ashrafi M, Yazdi RS, Ezabadi Z. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertil. Steril. 93(4), 1208–1214 (2009).
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 93(5), 1696–1701 (2008).
   PubMed Web of Science ®Google Scholar
• Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am. J. Clin. Nutr. 72(3), 690–693 (2000).
   PubMed Web of Science ®Google Scholar
• Arunabh S, Pollack S, Yeh J, Aloia JF. Body fat content and 25-hydroxyvitamin D levels in healthy women. J. Clin. Endocrinol. Metab. 88(1), 157–161 (2003).
   PubMed Web of Science ®Google Scholar
• Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res.Clin. Pract. 27(3), 181–188 (1995).
   PubMed Web of Science ®Google Scholar
• Isaia G, Giorgino R, Adami S. High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 24(8), 1496 (2001).
   PubMed Web of Science ®Google Scholar
• Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int. J. Clin. Pract. 57(4), 258–261 (2003).
   PubMed Web of Science ®Google Scholar
• Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am. J. Clin. Nutr. 79(5), 820–825 (2004).
   PubMed Web of Science ®Google Scholar
• Hahn S, Haselhorst U, Tan S et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes 114(10), 577–583 (2006).
   PubMed Web of Science ®Google Scholar
• Bourlon PM, Billaudel B, Faure-Dussert A. Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J. Endocrinol. 160(1), 87–95 (1999).
   PubMed Web of Science ®Google Scholar
• Bourlon PM, Faure-Dussert A, Billaudel B. The de novo synthesis of numerous proteins is decreased during vitamin D3 deficiency and is gradually restored by 1, 25-dihydroxyvitamin D3 repletion in the islets of langerhans of rats. J. Endocrinol. 162(1), 101–109 (1999).
   PubMed Web of Science ®Google Scholar
• Hahn S, Haselhorst U, Tan S et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp. Clin. Endocrinol. Diabetes 114(10), 577–583 (2006).
   PubMed Web of Science ®Google Scholar
• Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 61(5), 946–951 (1985).
   PubMed Web of Science ®Google Scholar
• Barr S, Hart K, Reeves S, Jeanes Y. Dietary intake, body composition and physical activity levels in women with polycystic ovary syndrome compared with healthy controls. J. Hum. Nutr. Diet. 21(4), 377 (2008).
   Google Scholar
• Douglas CC, Norris LE, Oster RA, Darnell BE, Azziz R, Gower BA. Difference in dietary intake between women with polycystic ovary syndrome and healthy controls. Fertil. Steril. 86(2), 411–417 (2006).
   PubMed Web of Science ®Google Scholar
• Hirschberg AL, Naessen S, Stridsberg M, Bystrom B, Holtet J. Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecol. Endocrinol. 19(2), 79–87 (2004).
   PubMed Web of Science ®Google Scholar
• Moran LJ, Noakes M, Clifton PM et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J. Clin. Endocrinol. Metab 89(7), 3337–3344 (2004).
   PubMed Web of Science ®Google Scholar
• Morgan J, Scholtz S, Lacey H, Conway G. The prevalence of eating disorders in women with facial hirsutism: an epidemiological cohort study. Int. J. Eat. Disord. 41(5), 427–431 (2008).
   PubMed Web of Science ®Google Scholar
• Naessen S, Carlstrom K, Garoff L, Glant R, Hirschberg AL. Polycystic ovary syndrome in bulimic women--an evaluation based on the new diagnostic criteria. Gynecol. Endocrinol 22(7), 388–394 (2006).
   PubMed Web of Science ®Google Scholar
• Rashidi B, Haghollahi F, Shariat M, Zayerii F. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwan. J. Obstet. Gynecol. 48(2), 142–147 (2009).
   PubMed Web of Science ®Google Scholar
• Firouzabadi R, Aflatoonian A, Modarresi S, Sekhavat L, Mohammad Taheri S. Therapeutic effects of calcium & vitamin D supplementation in women with PCOS. Complement Ther. Clin. Pract. 18(2), 85–88 (2012).
   PubMedGoogle Scholar
• Ardabili HR, Gargari BP, Farzadi L. Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr. Res. 32(3), 195–201 (2012).
   PubMed Web of Science ®Google Scholar
• Rahimi-Ardabili H, Pourghassem GB, Farzadi L. Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency. J. Endocrinol. Invest. 36(1), 28-32 (2013).
   PubMed Web of Science ®Google Scholar
• Spinelli A, Talamanca IF, Lauria L. Patterns of contraceptive use in 5 European countries. European Study Group on Infertility and Subfecundity. Am. J. Public Health 90(9), 1403–1408 (2000).
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Schulz KF, Curtis KM. Steroidal contraceptives: effect on bone fractures in women. Cochrane. Database Syst. Rev. (7), CD006033 (2011).
   Google Scholar
• Tremollieres F. Impact of oral contraceptive on bone metabolism. Best Pract. Res. Clin. Endocrinol. Metab. 27(1), 47–53 (2013).
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Martinez de Osaba MJ, Pons F, Fortuny A. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormone profile after 1-year use. Metabolism 46(4), 437–440 (1997).
   PubMed Web of Science ®Google Scholar
• Gregoriou O, Bakas P, Konidaris S, Papadias K, Mathiopoulos D, Creatsas G. The effect of combined oral contraception with or without spironolactone on bone mineral density of hyperandrogenic women. Gynecol. Endocrinol. 14(5), 369–373 (2000).
   PubMed Web of Science ®Google Scholar
• Lupoli G, Di Carlo C, Nuzzo V et al. Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass. J. Endocrinol. Invest. 20(8), 493–496 (1997).
   PubMed Web of Science ®Google Scholar
• Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane. Database Syst. Rev. (4), CD000194 (2003).
   Google Scholar
• Carbone LD, Cross JD, Raza SH et al. Fracture risk in men with congestive heart failure risk reduction with spironolactone. J. Am. Coll. Cardiol. 52(2), 135–138 (2008).
   PubMed Web of Science ®Google Scholar
• Gregoriou O, Bakas P, Konidaris S, Papadias K, Mathiopoulos D, Creatsas G. The effect of combined oral contraception with or without spironolactone on bone mineral density of hyperandrogenic women. Gynecol. Endocrinol. 14(5), 369–373 (2000).
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Zamberlan N et al. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. J. Clin. Endocrinol. Metab. 84(4), 1250–1254 (1999).
   PubMed Web of Science ®Google Scholar
• Rejnmark L. Bone effects of glitazones and other anti-diabetic drugs. Curr. Drug Saf. 3(3), 194–198 (2008).
   PubMedGoogle Scholar
• Ravn P, Haugen AG, Glintborg D. Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. Minerva Endocrinol. 38(1), 59–76 (2013).
   PubMed Web of Science ®Google Scholar
• Bechtold S, Dalla PR, Putzker S et al. Effect of antiandrogen treatment on bone density and bone geometry in adolescents with polycystic ovary syndrome. J. Pediatr .Adolesc. Gynecol. 25(3), 175–180 (2012).
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87(6), 2784–2791 (2002).
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M. Thiazolinedione treatment in polycystic ovary syndrome. Gynecol. Endocrinol. 26(11), 791–803 (2010).
   PubMed Web of Science ®Google Scholar
• Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146(3), 1226–1235 (2005).
   PubMed Web of Science ®Google Scholar
• Jackson SM, Demer LL. Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett. 471(1), 119–124 (2000).
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355(23), 2427–2443 (2006).
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M, Gamble G et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 92(4), 1305–1310 (2007).
   PubMed Web of Science ®Google Scholar
• Nybo M, Preil SR, Juhl HF et al. Rosiglitazone Decreases Plasma Levels of Osteoprotegerin in a Randomized Clinical Trial with Type 2 Diabetes Patients. Basic Clin. Pharmacol. Toxicol. 109(6), 481–485 (2011).
   PubMed Web of Science ®Google Scholar
• Park JS, Cho MH, Nam JS et al. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur. J. Endocrinol. 164(1), 69–74 (2011).
   PubMed Web of Science ®Google Scholar